GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
52.21
-4.06 (-7.22%)
At close: Jun 5, 2026, 4:00 PM EDT
52.50
+0.29 (0.56%)
After-hours: Jun 5, 2026, 5:14 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $102.25M in the quarter ending March 31, 2026, with 17.38% growth. This brings the company's revenue in the last twelve months to $442.68M, up 34.09% year-over-year. In the year 2025, GeneDx Holdings had annual revenue of $427.54M with 39.97% growth.
Revenue (ttm)
$442.68M
Revenue Growth
+34.09%
P/S Ratio
3.50
Revenue / Employee
$340,522
Employees
1,300
Market Cap
1.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 427.54M | 122.09M | 39.97% |
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | 196.17M | 62.83M | 47.12% |
| Dec 31, 2018 | 133.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.14B |
| Sotera Health Company | 1.19B |
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| Veracyte | 541.74M |
| CareDx | 412.82M |
| Twist Bioscience | 409.48M |
| Castle Biosciences | 339.92M |
WGS News
- 1 day ago - GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSS - PRNewsWire
- 10 days ago - GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 16 days ago - Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud - GlobeNewsWire
- 4 weeks ago - GeneDx price target lowered to $85 from $153 at Craig-Hallum - TheFly
- 4 weeks ago - GeneDx Holdings Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 4 weeks ago - GeneDx price target lowered to $55 from $60 at TD Cowen - TheFly
- 4 weeks ago - GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks - TheFly
- 4 weeks ago - GeneDx price target lowered to $70 from $100 at Guggenheim - TheFly